Cyprus Journal of Medical Sciences
Original Article

Prognostic Value of the Uric Acid Level and Its Effect on Survival in Stage I–III Gastric Cancer

1.

Clinic of Gastroenterologic Surgery, Türkiye Yüksek İhtisas Training and Resarch Hospital, Ankara, Turkey

2.

Clinic of General Surgery, Dr.Abdurrahman Yurtaslan Ankara Oncology Training and Resarch Hospital, Ankara, Turkey

Cyprus J Med Sci 2019; 4: 169-172
DOI: 10.5152/cjms.2019.901
Read: 93 Downloads: 67 Published: 23 December 2019

BACKGROUND/AIMS

Uric acid is the product of purine metabolism. In this study, we investigated the prognostic value of serum uric acid value on disease-free and overall survival (DSF and OS) in gastric cancer.

 

MATERIAL and METHODS

The records of 110 patients who underwent surgery for Stage I–III gastric cancer between 2012 and 2014 were retrospectively analyzed.

 

RESULTS

The average follow-up period was 42 months in 110 patients studied. The mean age was 63.7±11.6 years. Seventy percent of patients were male, and 43% underwent total and 57% subtotal gastrectomy. Most of gastric tumors were located in the distal stomach (56%), 24% in cardia, and 19% in corpus. While the tumor size was found to be larger than 4 cm in 60% of the patients and larger than 8 cm in 20%, according to the TNM system, 11% were Stage I , 29% Stage II, and 60% Stage III. Metastatic/excised lymph node ratio is <0.3 in 59% of patients. The mean uric acid level was 4.63±1.44. The cut-off values of uric acid were studied as 4 and 6.

 

CONCLUSION

When the mean distribution of the OS and DFS values according to uric acid groups was examined, there was no statistically significant difference between the groups (p>0.05). In our study, while the uric acid value was not found to be effective in DSF and OS, the stage, metastatic lymph node ratio, tumor size, and localization were found to be effective factors in OS.

 

Cite this article as: Üstüner MA, Karaman N, Aksel B, Doğan L. Prognostic Value of the Uric Acid Level and Its Effect on Survival in Stage I–III Gastric Cancer. Cyprus J Med Sci 2019; 4(3): 169-72.

Files
ISSN2149-7893 EISSN 2536-507X
3